Annual Report 2009/2010 Geschäftsbericht 2009/2010 ... - biolitec AG

14 The Company Das Unternehmen
Important events in 2009/2010
At the conference of the “Deutsche Gesellschaft für Phlebologie” as well as the “Union Internationale de
Phlebologie”, which took place between 31 August 2009 and 4 September 2009 in Monaco, biolitec was
able to convince with its ELVeS® RADIAL-fiber which by now is standard amongst German physicians.
At the “Kongress der Deutschen Gesellschaft für Urologie” which took place between 16 and 19 September
2009 in Dresden, biolitec presented laser systems and fibers for the treatment of benign prostate
hyperplasia with focus on the TWISTER-fiber. Also at the international healthcare exhibition MEDICA
taking place between 18 and 21 November in Duesseldorf, biolitec was able to successfully present different
laser applications. In the main focus of interest was the new hemorrhoid treatment method LHP
(Laser hemorrhoidoplasty). In November 2009 biolitec appointed the Urological Center at Alice-Hospital
in Darmstadt to a Center of Excellence for laser treatment of benign prostate hyperplasia. The treatment
of varicose veins with the ELVeS®-RADIAL was main focus at the “Bonner Venentagen“ taking place
at 19/20 February 2010. In March 2010 biolitec was able to achieve a major success in the Netherlands
because our anti-tumor drug FOSCAN® was added to list of expensive medical drugs which are reimbursed
by the medical insurances.
The beginning of a multi-center study conducted in the field of prostate laser treatment beginning
March 2010 was another success. After a kick-off meeting in Istanbul the international committee of
urology experts started a first study with the world’s first urology laser with two combinable wave
lengths.
In June 2010 a study was published which showed that the treatment of benign prostate hyperplasia
with biolitec lasers – compared to other lasers – does not mean higher risks of erectile dysfunctions and
fertility.
Dividend politic
For the fiscal year 2009/2010 the Executive Board and Supervisory Bord are going to propose a dividend
at the General Meeting. In the past few years the cash positions of the company were applied for the
aggressive growth strategy. It should to be the main point for the future. Dividend payments are conceivable
in future if in later years the company’s profits due to financing growth were not needed. The
decision is always pending of the current results, the liquidity requirements and the general basic conditions.
Key Factors 2009/2010
Share price - high (Xetra) Euro 5.00
Share price - low (Xetra) Euro 3.45
Market capitalisation (Xetra, 30.06.10) Euro 36.55 Mio.
Amount of shares 10,515,750 shares
ISIN DE0005213409